NCT03981536 - A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

November 2, 2020

Study Completion Date

November 2, 2020

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

AP-101

Administered by intravenous infusion (IV)

Trial Locations (3)

London Health Sciences Centre, University Hospital, London

Sunnybrook Health Sciences Centre, Toronto, Toronto

Montreal Neurological Institute & Hospital, Montreal